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Available online 3 June 2015AbstractThe artificial generation of tissues, organs, or even more complex living organisms was throughout the history of mankind a
matter of myth and dream. During the last decades this vision became feasible and has been recently introduced in clinical
medicine. The interest and attention that this rapidly developing area has received are based on the vision that the growing un-
derstanding of tissue healing and the achievements of biotechnology will be of profound therapeutic relevance. Clinically,
reconstructive surgery has arrived at a standard of care that allows for repair and restoration of the vast majority of tissues/organs
with established techniques. The real challenge of tissue engineering in clinical treatment is the reduction of surgical morbidity by
the application of biological signals or bio-artificial components cultivated from the patient's own cells, that can replace the lost
body part or accomplish its repair without the need for autogenous tissue transfer. Initially, activities in this area were mainly
focused on cell-based approaches aiming at the generation of tissue-like constructs by combining ex vivo expanded cell populations
with various types of scaffolds. Today, the field of tissue engineering has expanded tremendously, in that not only cells and scaffolds
but also growth factors, controlled release carriers, engineering of biomaterials and many other areas of basic and applied research
are considered to be part of the field of tissue engineering.
© 2015, Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
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The artificial generation of tissues, organs, or even
more complex living organisms was throughout the
history of mankind a matter of myth and dream. Dur-
ing the last decades this vision became feasible and has
been recently introduced in clinical medicine. Old
stories from the Greek mythology e.g., the generation
of Prometheus may be considered as early reportsE-mail address: Lydia.nabil@dent.alex.edu.eg.
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1687-8574/© 2015, Hosting by Elsevier B.V. on behalf of the Faculty of Drepresenting the idea of regeneration of living creatures
from living or nonliving specimens/organs. Later on, as
science and medicine progressed, a multitude of stor-
ies, reports, paintings, and films dealt with the idea that
humans could create life by modern “scientific” mea-
sures. A prominent newer example in literature and
film is the story of Frankenstein, written by Mary
Shelley in (1818), describing the vitalization of a
creature, reassembled from different body parts [1].
The term “tissue engineering” was up to the mid
1980's loosely applied in the literature in cases of
surgical manipulation of tissues and organs or in aentistry, Tanta University.
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were used. The term “tissue engineering” as it is
nowadays used was introduced in medicine in 1987. A
key point in tissue engineering was given by the close
cooperation between Dr. Joseph Vacanti from Boston
Children's Hospital and Dr. Robert Langer from M.I.T,
whose article in “Science”, describes the new tech-
nology, and can be referenced as the beginning of this
new biomedical discipline [1].
The interest and attention that this rapidly devel-
oping area has received are based on the vision that the
growing understanding of tissue healing and the
achievements of biotechnology will be of profound
therapeutic relevance. In clinical reality, reconstructive
surgery has arrived at a standard of care that allows for
repair and restoration of the vast majority of patients
with established techniques; the challenge of tissue
engineering in clinical treatment is the reduction of
surgical morbidity by the application of biological
signals or bio-artificial components cultivated from the
patient's own cells, that can replace the lost body part
or accomplish its repair without the need for autoge-
nous tissue transfer [2].
The term “tissue engineering” was initially defined
by the attendees of the first NSF (National Science
Foundation) sponsored meeting in 1988 as “application
of the principles and methods of engineering and life
sciences toward fundamental understanding of struc-
tureefunction relationship in normal and pathological
mammalian tissues and the development of biological
substitutes for the repair or regeneration of tissue or
organ function.” In 1993, Langer and Vacanti [3] sum-
marized the early developments in this field and defined
tissue engineering as “an interdisciplinary field that
applies the principles of engineering and life sciences
toward the development of biological substitutes that
restore, maintain or improve tissue or organ function.”
James Alexander Thomson (born December, 1958)
is an American developmental biologist best known for
deriving the first human embryonic stem cell (SC) line
in 1998 and for deriving human induced pluripotent
stem (iPS) cells in 2007. Human embryonic stem cells
have the ability to divide unlimitedly while maintain-
ing the potential to differentiate into different types of
body cells. This remarkable potential makes them
useful for basic research on the function of the human
body, for drug discovery and testing, and as a source of
cells and tissues for transplantation medicine [4,5].
The basic premise of regenerative medicine or tis-
sue engineering is that a practitioner could provide a
new construct to replace lost tissue whether that tissue
be bone, skin, mucosa, tendon, cartilage, heart muscle,liver, entire solid organs, or composite tissues. Various
terms have been used to describe activities involved in
repairing and regenerating tissues, wholly or partly by
using cells, proteins, matrices, signaling molecules or
other strategies. “Regenerative medicine”, “reparative
medicine”, and “tissue engineering” have been used,
somewhat interchangeably, to describe these activities
over the past several decades [6].
2. Basic principles of regenerative medicine
To regenerate new tissues within a specific envi-
ronment, 3 basic tools are required: the cells, a scaf-
fold, and the signaling molecules. Regeneration of
tissues is a complex and highly orchestrated process
that, nevertheless, proceeds along a rather uniform
pathway including the three well known steps of
inflammation, proliferation, and remodeling. During
this process biological signals accomplish the increase
in cell numbers that fill the defect or cover the wound.
At the same time, specialization of the newly formed
tissue-occurs through morphogenic signals which
induce the tissue specific differentiation [3].
Most of the biological signals that increase both
proliferation and induce differentiation of cells are
conveyed by polypeptide growth factors. These growth
factors are supplied by either local cells or by circu-
lating cells and blood components such as macro-
phages and platelets. Moreover, growth factors
originate from the extracellular matrix (ECM) where
they are stored and released during tissue remodeling
and repair. During this process, the extracellular matrix
serves an additional purpose by providing a three-
dimensional scaffold for the migration of cells and
their arrangement in a tissue-specific manner. In this
way, cells, signaling molecules, and the ECM are
closely linked and form the basis of tissue homeostasis
and regeneration in vivo [3].
When these three components are transferred to the
in vitro environment of tissue-engineered constructs,
the extracellular matrix is replaced by synthetic or
natural scaffolds which are used to accommodate and
arrange the cells in a three-dimensional fashion. The
triad of cells, signals, and scaffolds thus makes up the
“classic” tissue engineering triad (Fig. 1) [3].
However, beyond these three components, angio-
genesis and vascularization play an important role in
cellular behavior and tissue repair, not only because
blood supply is necessary for cell survival and devel-
opment, but also because vessels provide a reservoir of
undifferentiated perivascular cells that are recruited
during tissue repair [2].
Fig. 1. “Classic” tissue engineering triad.
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The area of regenerative medicine that has received
the most attention for the craniomaxillofacial region is
bone regeneration with cellular techniques, biomaterial
replacement, or signaling molecule use [7].
Autogenous grafting has been considered the gold
standard for bone replacement in the craniomax-
illofacial region over the years. Surgical specialists
have been looking for bone substitutes to avoid donor
site morbidity and provide a more convenient way to
regenerate defects, whether they are from congenital
deformities, acute trauma, chronic nonunion, or
resection of pathology [8].
Allogeneic bone grafts are suitable to some extent
for more simple defects, but they still have several
drawbacks, such as the cost, the less than ideal me-
chanical properties, the risk of disease transmission,
and the need to procure the material from limited
cadaveric specimens [8].
For most craniomaxillofacial defects of signifi-
cance, allografts and xenografts have little purpose if
one compares outcomes with autogenous sources.
Grafting a maxillary/alveolar cleft site is typically
performed with autogenous bone from the iliac crest.
Previous attempts to use allogeneic bone grafts or xe-
nografts have not had the success rates seen with
autogenous grafting, and as a result, these techniques
are not often used. Any option must surpass the success
of autogenous grafting while providing a solution that
also limits morbidity [9].
To engineer a substitute, it is necessary to regenerate
bone in a manner by which the materials can survive
through the initial phases of healing and implantation.
This generally means that bone must form reasonably
quickly and that the typical cellular, biochemical, andbiomechanical challenges must be overcome in a given
region. For example, the cranial vault is essentially a non-
weight-bearing and nonfunctional bone when compared
with the mandible. A critical size defect of the cranial
vault is likely to sustain less biomechanical force than a
critical size defect of the mandible. Although the cra-
nium and mandible have excellent blood supply in the
region, bacterial contamination is much more of an issue
in the mandible than in most areas of the cranium.
Consequently, the 3-dimensional (3D) construct that
provides the structural support for the reconstruction
must be suited to meet the biomechanical demands and
provide an appropriate environment for regeneration [7].
Autogenous grafting has done this fairly well, but
even microvascular tissue transfer often fails to provide
the ideal 3D structure that completely restores the defect
back to full functionality and meets the aesthetic de-
mands. Procedures that have provided BMP-2 to a defect
site in the craniomaxillofacial region often produce bone,
but in an unpredictable fashion. These reconstructions
frequently lack the desired 3-dimensional structure. New
efforts are aimed at designing novel 3D functional scaf-
folds exhibiting all the desired biofunctional attributes of
biocompatibility, bioactivity, safety, and internal and
external micro- and macrostructure combined with the
desired spatial and temporal pharmacokinetic transport
response. Consequently, novel biocompatible scaffolds
are available that serve as a home for cells or proteins
while also serving as smart delivery systems to address
some of these shortcomings [7].
2.2. Tissue engineering components
A. Biomaterials:
i. Biomaterial tissue interaction
Biomaterials are implanted to improve tissue func-
tion or to enhance tissue repair. In reconstructive sur-
gery they are used to fill defects, to bridge gaps, or to
cover wounds. They may function as scaffolds for
tissue ingrowth and thereby enhance tissue regenera-
tion or act as stabilizing devices to fix or join loose
tissue parts [2].
When a biomaterial is inserted into living tissues, a
cascade of events is initiated that starts with the
adsorption of biomolecules to the material's surface.
Important characteristics for the immediate interaction
with the in vivo environment are surface charge and
surface energy of the material. An increase in surface
energy improves the wettability of the material surface
facilitating the adsorption of serum proteins and other
biomolecules such as fibronectin [10].
Fig. 2. SEM image of a coralline CaCO3 scaffold [2].
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that is accompanied by the adsorption of biomolecules,
is one of the most important preconditions for cells to
become attached to the material surface and to estab-
lish tissue contact with the biomaterial. Surface energy
and surface charge themselves depend on the material
composition and on the surface structure. Metals and
mineralized materials commonly have a negative sur-
face charge under physiological conditions due to the
presence of oxide molecules on their surface. This
results in the adsorption of positively charged mole-
cules to the biomaterial surface. While polymers such
as polylactic acid (PLA) have a rather low surface
energy and hence a rather hydrophobic surface char-
acteristic, the higher surface energy of many metals
and ceramics in particular renders these surfaces hy-
drophilic which can enhance tissue integration from
the material side [10].
Another feature that affects the interaction between
biomaterials and living tissues is the surface texture.
Microrough surfaces have been shown to affect cellular
attachment and differentiation. Several factors are
considered to contribute to the improved performance
of these surface modifications when compared to non-
structured surfaces. One positive effect of micro-
structured surfaces comes through the increase in sur-
face energy that is associated with increased surface
roughness and hence improved wettability. Another
positive effect on cellular behavior is mediated through
the microtexture itself. This has been shown in surface
modifications of titanium implants [11].
Different degrees of surface roughness have been
shown to modify cellular production of receptors that
mediate adhesion to titanium surfaces. Moreover,
increased secretion of molecules indicating osteogenic
differentiation of cells in contact with the microtextured
surface as well as enhanced production of cytokines
involved inbone formationhas been reported invitro [12].
In this way material science in biotechnology can
contribute substantially to the success of tissue engi-
neering by optimizing immediate and late interactions
both between seeded cells in vitro and living tissues
after implantation in vivo [2].
ii. Scaffolds:
Tissue in the craniomaxillofacial region is varied in
composition, but in its simplest definition, it consists of
a matrix and various cell types [13].
The matrix represents a 3D structure or scaffold for
cells, which provides them with a specific environment
and architecture for a given functional purpose [14].The structure also serves as a reservoir of water,
nutrients, cytokines, and growth factors. When one
applies these concepts to tissue engineering in the
craniofacial skeleton to restore function or regenerate
the bone tissue, the scaffold will act as a temporary
matrix or template for cell proliferation, extracellular
matrix deposition, bone regeneration, and remodeling
until the mature bony tissue is regenerated [15,16].
During this process, the scaffold acts as a template for
the vascularization [17,18].
In general, the materials that are used as scaffolds
can be divided into organic and inorganic materials.
Organic materials may originate from natural pre-
cursors such as collagen, chitosan, or silk or can be
produced from synthetic polymers such as PLA and
polyglycolic acid (PGA). Inorganic materials
commonly consist of metals, alloys, or mineral com-
positions. Mineral compositions may vary consider-
ably containing mixtures of calcium, sodium,
potassium, silicates, magnesium, aluminum, zirconia,
carbonates, or phosphates. Mineralized scaffolds may
be purely synthetic or derived from natural precursors
such as corals, algae, or bovine bone [3,13].
Nanostructured forms of calcium phosphates can
attach growth factors, including 3D architectures of
tailored natural polymer-based gels and cements,
exploiting the enhanced bioactivity and resorption
potential. These novel cements are also being studied
as next-generation systems for tissue engineering. The
scaffolds ideally need to accomplish several goals that
include biocompatibility, appropriate mechanical
strength, and appropriate degradation [19].
Porosity and interconnectivity: are also important
for an efficient and effective diffusion of nutrients and
gases (Figs. 2 and 3). These properties aid in the
Fig. 3. A bioactive glass scaffold with an interpenetrating porous
structure. A “pores within pores” structure supports the flow of nu-
trients and ingress of cells within the core of the scaffold.
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scaffold. Because of metabolic demands of the bone,
high rates of mass transfer are expected to occur with
the regenerative process. The scaffold must have a
structure that allows for efficient removal of these
waste products [20]. The pore size of scaffold material
also plays an important role in cell proliferation and
cell distribution throughout tissue regeneration [21].
Pore sizes are divided into micropores (<10 mm) and
macropores (>50e60 mm). Some have suggested an
optimal pore size between 200 and 400 mm [22].
Others have suggested that pore sizes up to 200 mm in
polyester membranes result in the best bone ingrowth.
The size of the pore has a significant effect on its
mechanical integrity and its ability to perform under
functional demands [23].
Pores and voids disrupt the continuity of the solid
phase and subsequently lower the solid phase density.
This weakening of the solid phase and reduced mass
density across the surface and bulk results in defects at
the atomic and molecular levels, causing the material
to fail more easily under reduced stresses in compari-
son to the denser (less porous) material. There is
considerable work in progress to maximize the strength
of the solid phase while maintaining porosity in the
range of 70% with biologically acceptable pore sizes
[7].
iii. Biofunctionalization
The fact that the initial interactions of biomaterials
with their host tissues are based on the adsorption of
biomolecules from the in vivo milieu on the material
surface has promoted the idea of enhancing theintegration of these materials by modifying the surface
conditions either by enhancing adsorption of these
molecules in vivo or by activating biomaterial surfaces
with biologically active molecules (BAM's). The stra-
tegies vary from altering the physical characteristics
through increased surface roughness to physicochem-
ical and/or chemical modification [24].
B. Cells
The strategy of cell-based approaches is to obtain a
small number of cells or a small tissue portion through
a minimally invasive procedure and to expand these
cells ex vivo to a volume that can be expected to form
the desired amount and type of tissue. Cell-based ap-
proaches are the most complex approaches of all en-
deavors in tissue engineering because, other than with
the application of growth factors, both the host tissue
and the biological quality of the seeded scaffolds that
are implanted are variable biological success factors.
The functionality of these biohybrid constructs de-
pends very much on the survival and the performance
of the implanted cells. Thus, besides the local condi-
tions at the recipient site, both the initial cell source
and the in vitro handling during cultivation of the
constructs are important for successful applications [2].
i. Mesenchymal Stem Cell Technology:
In vivo, the cell sources for tissue repair are stem
cells that are not yet terminally differentiated and have
a high proliferative potential. In contrast to embryonic
stem cells, which are pluripotent and can differentiate
into a large range of different tissues, adult stem cells
are already committed to a certain type of tissue such
as mesenchymal stem cells. These stem cells can still
differentiate into bone, cartilage, or fat cells, but are
limited to tissues of the connective tissue lineage and,
thus, are considered to be only multipotent. ESCs
(embryonic stem cells) are usually isolated from the
inner wall of the preimplantation blastocysts. These
embryonic cells in the early developmental stages are
more proliferative and are pluripotent because of their
indefinite amplification without the risk of dedifferen-
tiation. Ethical issues, immune rejection uncertainty,
and uncontrolled differentiation make embryonic stem
cell use challenging [25].
ASCs (Adult stem cells) reside in the fully differ-
entiated or adult tissues. ASCs have been procured
from the bone marrow, periosteum, muscle, fat, brain,
dental pulp, and skin. Several tissues, such as epithe-
lium, bone marrow, liver, and fat tissue have stem cell
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tained, isolated, and expanded ex vivo by in vitro
technology. Terminal differentiation after sufficient
expansion is then induced by conditioning supplements
in the culture media [26e29].
.Mesenchymal stem cells (MSCs) are immature and
undifferentiated cells that are commonly obtained from
bone marrow aspirates (Fig. 4) but can also be
retrieved from fat tissue and periosteum. The term
mesenchymal stem cell is not quite correct for this type
of adult stem cells and has undergone rephrasing
several times. Currently, adult stem cells derived from
bone marrow are called multipotent mesenchymal
stroma cells (MSCs) [30].
Stem cells derived from fat tissue are referred to as
adipose tissue-derived stem cells (ADSCs) and are
considered to have very similar properties to bone
marrow-derived stroma cells. Stroma cells are isolated
as mononuclear cells from bone marrow aspirates by
density gradient centrifugation and are separated from
hematopoetic stem cells, which are always retrieved
simultaneously, by their ability to adhere to the plastic
bottom of the culture dishes. Expansion is commonly
done by passaging the cells before growth becomes
subconfluent and subsequently replating them at low
density. Under these conditions MSCs maintain a
spindle-shape phenotype and form separate colonies of
fibroblastoid cells. The number of these colony-
forming units (CFUs) is considered as a measure for
the proliferative potential of the cell population [31].
After sufficient expansion, osteogenic (ascorbic
acid, dexamethasone, glycerophosphate) or chondro-
genic supplements (ascorbic acid, dexamethasone,Fig. 4. Bone marrow stroma cells attached to the bottom of the petri
dish 4 days after plating [2].proline, pyruvate) are individually used to induce the
respective differentiation of the expanded cells,
depending on the tissue that is supposed to be regen-
erated. Fat tissue for isolation of ADSCs is commonly
derived by liposuction. The technique of tissue har-
vesting has considerable impact on the viability of
retrievable ADSCs. The aspirate undergoes washing
and subsequent digestion using collagenase treatment.
After centrifugation and resuspension of the resulting
pellets, the cells are plated at low density of (100 cells/
cm2). CFUs resulting from this procedure can be ex-
pected to range between 0.1 and 5% of the retrieved
nucleated cells. Epithelial stem cells are more difficult
to isolate and expand [32].
ii. Induced Pluripotent stem cells (iPSC's):
Stem cell biology is changing rapidly, and the un-
derstanding of stem cell differentiation or dedifferen-
tiation of somatic cells is expanding greatly. Recent
advancement in research has transformed mature skin
cells into pluripotent cells by inserting just 4 genes,
Oct3/4, Klf4, Sox2, and c-Myc, into the cell nucleus.
These cells were called “induced pluripotent stem
cells”. Although more basic research is required to
acquire basic knowledge about these cells, they are
considered to be a major therapeutic possibility.
Cellular therapy is changing rapidly and future use of
these advanced technologies for craniofacial regener-
ation holds great promise for patients [33e35].
iii. Recombinant cells:
One of the weaknesses of cell-based approaches is
the fact that the implanted cells have to rely on the host
tissue to provide the biological signals and environ-
mental factors that are necessary to revascularize the
implanted constructs as rapidly as possible and at the
same time maintain the biological quality of the
implanted cells inside the scaffolds. This has prompted
the idea to use gene transfer to the seeded cells that
would allow for overexpression of the required growth
factors which make them less dependent from the level
of host tissue factors. Thus, the functionality of the
implanted devices could be increased and the thera-
peutic outcome improved [2].
iv. Differentiated Osteoblasts:
These cells are committed mesenchymal cells that
have been directed down the osteogenic lineage to
push the cell type closer to the final type desired. Using
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achieving rapid repair of defects, because the cells are
already differentiated. The main disadvantage is that
they have a limited capacity for proliferation, because
they are able to perform only a certain number of
replication cycles before the problem of dedifferenti-
ation arises. The presence of these cells may drive the
process locally and recruit additional cells from the
host to continue the process [11].
C. Growth factors:
Growth factors are proteins produced by cells that
act as signaling molecules on an appropriate cell to
carry out a desired function. These proteins activate the
cellular communications network and influence func-
tions, such as cell proliferation, matrix deposition, and
differentiation of tissues [36].
Growth factors have been shown to play a key role
in bone and cartilage formation, fracture healing, and
the repair of other musculoskeletal tissues. Their range
of activity varies considerably during embryogenesis,
postnatal growth, and adulthood. During embryonic
development, growth factors are involved in limb
patterning and morphogenesis of many organs, while
in postnatal life their role is restricted mainly to tissue
regeneration and repair [37].
Abnormalities in the genes that code for these
proteins cause various craniofacial skeletal dysostoses
(ie, Apert syndrome, Crouzon syndrome, and the
achondroplasia syndromes). The binding of a growth
factor to its receptor initiates intracellular signaling
that will lead to different events, such as the promotion
or prevention of cell adhesion, proliferation, migration,
and differentiation. This typically occurs by upregu-
lating or downregulating the synthesis of proteins and
receptors. Hence, these molecules are recognized as
fairly important for tissue formation and may play an
important role in regenerative medical approaches
[37e39].
In 1965, Urist made the observation that deminer-
alized bone matrix could produce bone formation when
placed in subcutaneous tissue. This capability was later
attributed to BMP [40].
Currently, the BMPs are grouped into the TGF-b
superfamily because of their similarities in protein
structure and sequence homology. BMPs are closely
associated with the bone matrix, and they are expressed
during the early phases of fracture healing. Their role
is to recruit mesenchymal stem cells to the healing site
and then differentiate them into the osteogenic lineage
for bone deposition. Although there are many BMPsdescribed, BMP-2, -4, -6 and -7 are the best studied in
craniofacial biology and are considered to have the
most potential for regeneration [39,41].
2.3. Growth factors used in maxillofacial
reconstruction
The therapeutic application of growth factors for the
repair of damaged tissue is used to enhance the level of
regeneration beyond the limit to which spontaneous
tissue repair has been downregulated in postnatal life.
Thus, defects that would otherwise not heal in life time
(“critical size defects”) are intended to be repaired
without the need for additional tissue transfer.
Many growth and differentiation factors of different
origins have been employed both in preclinical and
clinical tissue repair. When single growth factors are
intended for therapeutic application, recombinant
growth factors are commonly used. Recombinant
growth factors are identical to human growth factors
with respect to amino acid sequences and three
dimensional structure. They are produced by either
eukaryotic cells or bacteria (Escherichia coli) that have
been transfected/transduced with the respective gene
[42,43].
The majority of growth factors used in maxillofacial
reconstruction are directed towards the repair of
mesenchymal tissues. Some of them are also involved
in the interaction between mesenchymal tissue and
epithelium during mucosa repair. In particular, bone
regeneration is a clinical focus of tissue engineering
using growth factors. There are at least six growth
factors involved in bone regeneration that have been
used in maxillofacial reconstruction in a large number
of animal models [42e57].
 platelet-derived growth factor (PDGF)
 basic fibroblast growth factor (bFGF)
 insulin-like growth factor (IGF)
 transforming growth factor beta (TGFb)
 vascular endothelial growth factor (VEGF)
 bone morphogenetic proteins (BMPs)2.4. Craniofacial and dental tissue regeneration
There are 3 major approaches for regeneration of
craniofacial and dental tissues namely; recombinant
protein therapy, cell-based therapy and gene therapy.
First, recombinant protein therapy consists of
delivering the appropriate growth factor on a scaffold
in order to stimulate certain cells in the target site.
Fig. 5. Ex vivo gene therapy approach. Harvested cells from the
patient (differentiated cells or stem cells) are used for gene delivery
by genetic modification in vitro and then transplanted back into the
patient for treatment after being loaded on a scaffold.
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even eliminate the need for autogenous bone grafts
[58,59]. However, higher order species like humans
usually need higher concentrations of bone morpho-
genic proteins to achieve the same results in lower
order animal species. This may be attributed to slower
osteogenic potential, less availability or response of
osteoprogenitor cells in higher order species [60e62].
The second approach is cell-based therapy which
involves direct contribution to tissue regeneration, ge-
netic modification of cells to act as vehicles for gene
therapy and differentiation into various tissue types
[63].
An interesting feature of cells is what is called
“Plasticity”, which refers to the ability of adult stem
cells to differentiate into various tissue types according
to the gene expressed and the local environment [64].
This has also been proved to be possible even after
final differentiation has occurred [65].
The third approach is the gene therapy which is a
relatively new pattern in medicine with tremendous
therapeutic potential where specific genetic information
is delivered to the cells directing them to secrete a
certain protein product [66]. This approach involves two
important issues: the first is choosing the appropriate
gene encoding for the stimulant protein (where the
plasmids are usually used as gene delivery vehicles)
[67,68]. And the second issue is determining the method
of delivering the gene whether via a viral vector (espe-
cially Adenovirus on which various studies have been
performed) or a non-viral vector using chemical sup-
plements such as calcium phosphate complexes that
facilitate passage through the cell membrane. Alterna-
tively, lipofection has been employed which uses lipo-
somes that encase the plasmid vectors to pass through
the cell membrane. Liposomes bind to the cell mem-
brane and are incorporated through endocytosis [69,70].
Adenovirus is a double stranded-DNAvirus in which
highly efficient gene transfer can be accomplished.
After removal of pathogenic gene sequences from these
virus particles, their ability to deliver genetic material to
host cells is used to transfect the target cells with the
respective gene (Fig. 5). The major disadvantage of
adenoviral vectors is the immune response resulting
from expression of the viral proteins. A variety of viral
vectors is available, including adenoviruses (AVs),
adenoassociated viruses (AAVs), and retroviruses such
as lentiviruses (LVs). While adenoviral vectors remain
in the cytoplasm of the target cells, retroviral vectors
integrate their DNA permanently into the genome. In
this way, viral gene transfer using retroviral vectors is
more effective than using adenoviral vectors [69].Gene therapy can be accomplished by an in vivo
approach with its advantage of direct injection into the
target site but at the same time it carries the risk of non-
specific cellular targeting. Also, it can be performed by
the ex vivo approach which has the advantage of specific
cellular targeting but it is a more lengthy procedure with
the potential for contamination and other risks [71,72].
The use of gene transfer in tissue engineered devices
in oral and maxillofacial surgery has been performed so
far only in a few approaches at the preclinical level.
Experimental studies have used genetically modified
human marrow-derived stroma cells and mesenchymal
stem cells overexpressing BMPs [73,74].
2.5. Studies on the application of tissue engineering
to regeneration of maxillofacial/dental tissues: e pulp
regeneration
In cases of severe pulpitis, the capability of self-
regeneration or repair is limited because the odonto-
blasts that produce reparative dentin are destroyed. So,
regeneration of the dentin-pulp complex has been
investigated through the isolation and exploration of the
regenerative abilities of stem cells, thus new therapeutic
possibilities may be possible. In the past decade,
Regenerative endodontics has gained much attention as
it offers an alternative approach for treatment of
endodontically involved teeth by filling the canal with
vital tissues instead of artificial materials [75].
- Periodontal tissue regeneration:
In periodontitis, the periodontal attachment is
destroyed as a result of inflammation, and the
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periodontitis remains challenging. Therefore, gene
transfer approaches have been used to deliver several
growth factors that may regenerate the periodontal
ligament as platelet derived growth factor and BMP-7
[76,77].
In addition, Periodontal ligament stem cells
(PDLSC) from extracted teeth can recently be cultured,
expanded and differentiated in vitro, thus may have
important applications in achieving efficient dental
tissue regeneration [78].
- Gene therapy for repair of salivary gland function:
Salivary gland hypofunction, also known as xero-
stomia, occurs as a result of radiation therapy for head
cancer, Sj€ogren's syndrome or aging, and can cause a
variety of problems, including dental decay, bacterial
infection, mastication dysfunction, swallowing
dysfunction and reduced quality of life. That's why
research has been directed to salivary gland tissue
regeneration [79,80], where gene therapy using an
adenoviral vector has been used to increase the salivary
flow at irradiated regions [81,82] and more studies are
now directed to human trials [83e86].
- Bone regeneration:
The reconstruction of critical size mandibular bony
defects remains a challenge in oral and maxillofacial
surgery, so bone regeneration using cell-seeded scaf-
folds has been investigated [87e89].
In bone tissue engineering, periosteal cells from the
mandibular ramus and bone-derived cells from the
maxillary tuberosity have been used to produce bone in
sinus lift procedures and lateral rim augmentations in
preimplant surgery [90,91].
Cell-based approaches in combination with growth
factors e in particular BMPs e have been used for flap
prefabrication in major reconstructive procedures by
implantation into the latissimus dorsi muscle and
subsequent revascularized transfer to a segmental
defect of the mandible. These procedures may not be
cost effective yet when compared to the established
methods of revascularized tissue transfer for mandib-
ular reconstruction, but they add to the knowledge of
tissue engineering and may help to gather experience
of how the principles of tissue engineering can be
accommodated in the current strategies of maxillofa-
cial reconstruction [92].
- Cartilage regeneration:Cartilage tissue engineering in oral and maxillofa-
cial surgery is limited very much to the temporoman-
dibular joint (TMJ). Some recent reports have dealt
with tissue engineering of nasal cartilage, but most of
the current work is directed towards replacement of the
TMJ disc and condylar cartilage. One of the major
problems to overcome in tissue engineering of TMJ
cartilage is the specific structural requirements of tis-
sue engineered TMJ cartilage to withstand the in vivo
forces as well as the fixation and connection of
remaining ligaments. The mechanical properties of this
type of cartilage have to enable the tissue not only to
take pressure but also a high level of tension. Thus, the
characteristics of common hyaline cartilage that is
used by many tissue engineering approaches to replace
joint cartilage will not be appropriate to replace TMJ
cartilage [93,94].
- Epithelial tissue regeneration:
Engineering of epithelial tissue has moved from the
use of epithelial monolayer sheets in the 1980s to more
complex constructs that contain a stratified epithelium,
a continuous basement membrane, and a fibrous con-
nective tissue layer that supports the epithelium and
gives three-dimensional stability during handling and
healing. These engineered full thickness oral mucosa
constructs are commonly referred to as ex vivo pro-
duced oral mucosa equivalent (EVPOME) [95]. Clin-
ical tissue engineering of epithelium using EVPOME
preparations has been employed in intraoral applica-
tions such as vestibuloplasty, repair of superficial
postablative mucosal defects, and for prelamination of
free radial forearm flaps with subsequent transfer to the
oral cavity. Clinical results have shown a good to
excellent take rate with vascular ingrowth from the
recipient bed with the total wound healing time being
shorter than in the control defects covered with un-
seeded scaffolds only [96].
2.6. Use of bioreactors in maxillofacial tissue
engineering
Bioreactors can be defined as devices in which
biological or biochemical processes, or both, are re-
enacted under controlled conditions (for example,
pH, temperature, pressure, oxygen supply, nutrient
supply, and waste removal). Originally most bio-
reactors were developed to test biomaterials but some
of them were also invented with the objective of
extracorporal tissue growth. Various types of bio-
reactors have therefore been developed and tested for
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of larger three-dimensional tissues particularly require
the development of enlarged devices and systems that
allow cells to locate them in a three-dimensional space,
and at the same time satisfy the physicochemical de-
mands of large cell masses commonly connected to a
scaffold [97,98].
2.6.1. Bioreactor systems
The ideal bioreactor would need autologous mate-
rial and a scaffold as inputs and, after a defined culture
period, would output the required amount of the
required tissue. Bioreactors can be technically classi-
fied according to their design properties into two types;
closed systems and open systems (using conventional
dishes and flasks) [99].
In order to obtain reproducible and standardized
results, the culture conditions such as temperature, pH,
nutrient, and oxygen supply should be adjustable.
More advanced techniques as oxygen measurements,
substrate monitoring, flow determination, fluorescence
microscopy, and micro-computerized tomography are
now available during tissue regeneration using bio-
reactors [99].
2.6.2. Transportation of regenerated tissues
A transportation technique for cell sheets is neces-
sary in order to standardize regenerative medicine. And
since maintenance of the temperature and pressure is
critical for cell viability during long distance trans-
portation, several devices have been tested for use as
safe and efficient transportation containers. Examples
of such devices are those developed by Nozaki et al.
(2008) [100] and Oie et al. (2014) [101] for trans-
portation of the engineered tissues from a production
facility to a medical operation facility while main-
taining tissue viability and preventing contamination.
3. Future perspectives
Future studies are now directed to development of a
composite graft (skin, bone, cartilage, and muscle),
with associated nerve and blood vessels, which is
engineered from the host stem cells. A recent study by
Lee JS et al. (2014) [102], was done using 3D printing
of composite tissue with complex shape for ear
regeneration.
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